Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$82 Mln
P/E Ratio
--
P/B Ratio
2.45
Industry P/E
--
Debt to Equity
0.09
ROE
-1.08 %
ROCE
-100.58 %
Div. Yield
0 %
Book Value
5.56
EPS
-6.7
CFO
$-433.79 Mln
EBITDA
$-614.58 Mln
Net Profit
$-670.38 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Assembly Biosciences (ASMB)
| -31.43 | -0.73 | -23.10 | -14.47 | -22.80 | -45.31 | -24.09 |
|
BSE Sensex*
| 2.74 | 3.85 | 5.92 | 9.03 | 11.81 | 20.14 | 11.37 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Assembly Biosciences (ASMB)
| 59.73 | -36.92 | -44.21 | -61.49 | -70.43 | -9.55 | -49.82 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 35.89 | 6,904.81 | -- | 38.11 | |
| 70.95 | 7,574.08 | 58.3 | 23.56 | |
| 59.52 | 11,448.88 | 394.4 | 0.76 | |
| 8.25 | 9,704.70 | -- | -3.24 |
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are... in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study. The company also develops ABI-7423, an oral broad-spectrum non-nucleoside polymerase inhibitor that targets transplant-related herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California. Address: Two Tower Place, South San Francisco, CA, United States, 94080 Read more
CEO, President & Director
Mr. Jason A. Okazaki
CEO, President & Director
Mr. Jason A. Okazaki J.D.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Assembly Biosciences Inc (ASMB) stood at $ 119 Mln as on 31-Dec-24
The share price of Assembly Biosciences Inc (ASMB) is $10.82 (NASDAQ) as of 28-Apr-2025 16:00 EDT. Assembly Biosciences Inc (ASMB) has given a return of -22.8% in the last 3 years.
Assembly Biosciences Inc (ASMB) has a market capitalisation of $ 82 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Assembly Biosciences Inc (ASMB) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Assembly Biosciences Inc (ASMB) and enter the required number of quantities and click on buy to purchase the shares of Assembly Biosciences Inc (ASMB).
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study. The company also develops ABI-7423, an oral broad-spectrum non-nucleoside polymerase inhibitor that targets transplant-related herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California. Address: Two Tower Place, South San Francisco, CA, United States, 94080
The CEO & director of Mr. Jason A. Okazaki. is Assembly Biosciences Inc (ASMB), and CFO & Sr. VP is Mr. Jason A. Okazaki J.D..
There is no promoter pledging in Assembly Biosciences Inc (ASMB).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,122
|
|
|
932
|
|
|
731
|
|
|
670
|
| Assembly Biosciences Inc. (ASMB) | Ratios |
|---|---|
|
Return on equity(%)
|
-107.92
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
-140.87
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Assembly Biosciences Inc (ASMB) was $0 Mln.
$0.12
(
